Posters

Investigation of clinical outcomes after bilateral implantation of a hydrophobic trifocal intraocular lens FineVision Triumf (POD L GF)

Poster Details

First Author: N.Garzón SPAIN

Co Author(s):    F. Poyales   R. Pérez-Izquierdo   I. López-Brea   M. Romero           

Abstract Details

Purpose:

The purpose of this ongoing prospective multicenter clinical study is to evaluate first clinical outcomes after bilateral implantation of a hydrophobic trifocal non-toric intraocular lens (IOL), the new FINEVISION TRIUMF (POD L GF), PhysIOL sa, Belgium. Only clinical results from IOA Miranza will be given.

Setting:

Miranza IOA Madrid, Spain

Methods:

This ongoing prospective multicenter clinical study is planned for a maximum follow-up time of 12 years postoperative. The visual acuity and contrast sensitivity examinations were performed using Clinical Trial Suite (M&S Technologies, Niles, IL, USA). The first preliminary outcomes comprise manifest refraction, monocular visual acuity UDVA, CDVA (both at 4m), UNVA (40cm), DCNVA (40cm), UIVA (66cm), DCIVA (66cm), UIVA (80cm), DCIVA (80cm), defocus curves and contrast sensitivity with follow-up of 1 month and 6 months.

Results:

Preliminary results of 10 eyes at 1-2 months and 4 eyes at 4-6 months show mean Uncorrected Distance VA (UDVA) -0.04±0.07 and -0.07±0.03 logMAR respectively. Mean Corrected Distance VA (CDVA) -0.08±0.03 and -0.10±0.01 logMAR at 1-2 months and 4-6 months respectively. Photopic Mean UIVA (80cm) 0.06±0.04 and 0.09±0.05, UIVA (66cm) 0.08±0.08 and 0.05±0.04, UNVA is 0.20±0.11 and 0.17±0.06 at 1-2 months and 4-6 months respectively. DCIVA at 80cm, 66cm and DCNVA 0.04±0.08 and 0.03±0.07 logMAR, 0.06±0.09 and 0.04±0.02, 0.16±0.11 and 0.09±0.06 at 1-2 months and 4-6 months respectively. Mesopic outcomes, further outcomes and longer follow-up will be presented at session.

Conclusions:

Implantation of the hydrophobic trifocal intraocular lenses FINEVISION TRIUMF allows for a safe and efficient restoration of near, intermediate, and far visual acuity on patients undergoing lens exchange. Preliminary results indicate spectacle independence. It is expected to see further superior intermediate visual acuity with TRIUMF with long-term outcomes and larger patient cohort.

Financial Disclosure:

None